Cygnus
Executive Summary
Ortho-McNeil agrees to acquire Cygnus' drug delivery technology platform and most of its products, including the nicotine patch Nicotrol, two hormone replacement transdermal products and the contraceptive patch Edra. McNeil Consumer Healthcare already markets Nicotrol in the U.S. Cygnus will receive $20 mil. at closing and the remaining $55 mil. will be contingent on the attainment of technical, regulatory and commercialization milestones for Edra. Ortho-McNeil expects to file an NDA for Edra in January. Cygnus plans to focus on its GlucoWatch device, which monitors glucose levels and is up for an FDA advisory committee review Dec. 6
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth